MedTrace Logo

Real-life Data of Cardiovascular Events Occuring During Degarelix Therapy for Prostate Cancer

NCT02229253 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 112

Last updated 2017-11-27

No results posted yet for this study

Summary

Patients with prostate cancer and a history of cardiovascular disease treated with degarelix for their prostate cancer, will be followed for a period of one year. In this real-life, non-interventional trial, any cardiovascular events occurring during degarelix therapy will be documented.

Conditions

  • Advanced Hormone Sensitive Prostate Cancer

Interventions

DRUG

degarelix

Sponsors & Collaborators

  • Ferring Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Clinical Development Support · Ferring Pharmaceuticals

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2017-10-04
Completion
2017-10-04

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02229253 on ClinicalTrials.gov